Natera, Inc. · NASDAQ:NTRA

Natera — Fact Sheet (September 2015)

4 slides from Natera's fact sheet, September 2015

  1. Slide 1: Anora miscarriage test (POC) for Products of Conception

    anora’ miscarriage test (POC) for Products of Conception In a recent study, 95% of patients who had chromosome analysis for miscarriage were glad they did; two-thirds who did not wished they had. (Lathi et al. ASRM. 2011) 8 natera Conceive. Deliver.

  2. Slide 2: With chromosome analysis, the etiology was identified in 62% of miscarriages

    With chromosome analysis, the etiology was identified in 62% of miscarriages that would otherwise have been unexplained Without chromosome analysis With chromosome analysis 20% 20% 18% 80% 62% Unexplained Fetal chromosome abnormality Other maternal factors Unexplained Other maternal factors es lts a

  3. Slide 3: Molar pregnancy frequency and triploidy cases by origin

    FREQUENCY IN ETHNICITY PREGNANCY 5 Caucasian 1/1,000 Southeast Asian 1/125 Annual Molar 6,000 per Pregnancies in the US year 39% 61% 412 total triploidy cases 253 Maternal (61%) 39% 159 Paternal (39%) 61% 412 total triploidy cases 253 Maternal (61%) 159 Paternal (39%)

  4. Slide 4: Natera's Comprehensive DNA-based Prenatal Screening Solution

    Natera’s Comprehensive DNA-based Prenatal Screening Solution Pregnancy loss is difficult. Anora’s answers can help. For patients considering another pregnancy, Natera also offers: ¢ Horizon™ carrier screening, which can tell her and her partner if they might be at risk to pass on specific genetic di

Natera — Fact Sheet (September 2015) on 6ix